Overview of Patent 10,576,165
United States Patent 10,576,165 (the '165 patent) titled "Methods of treating tumors with an HSP90 inhibitor," granted on February 4, 2020, claims a novel approach for treating cancer via heat shock protein 90 (HSP90) inhibition. The patent targets a specific class of HSP90 inhibitors, emphasizing particular chemical structures and treatment regimens.
Scope of the Patent: Claims Breakdown
The patent includes 23 claims divided into independent and dependent claims, with the core claims focusing on:
- Chemical compounds: Small molecule HSP90 inhibitors with defined chemical structures, notably those with specific substitutions and stereochemistry.
- Methods of treatment: Administration of these inhibitors to a subject with a tumor, including dosage, frequency, and combination with other therapies.
- Use of compounds: Application in treating various cancers such as breast, lung, colon, and prostate tumors.
Key Independent Claims
- Claim 1: A compound comprising a structure characterized by a core scaffold, with specified substitutions at particular positions, designed to inhibit HSP90 activity.
- Claim 10: A method of treating a tumor in a mammal involving administering a therapeutically effective amount of a compound as claimed in Claim 1.
- Claim 14: Use of such compounds for manufacturing a medicament for treating tumors.
Dependent Claims
- Specify particular chemical variations, such as specific groups attached at defined positions, purity levels, or formulations.
- Claim 20 focuses on combination therapy, including co-administration with chemotherapy agents or other targeted therapies.
- Claims 21-23 specify dosing regimens, routes of administration, and treatment durations.
Patent Landscape: Related Patents and Applications
The '165 patent fits into a broader patent landscape centered on HSP90 inhibitors, a well-researched class of anti-cancer agents. Key points include:
Major Patent Families and Similar Patents
| Patent Number |
Title |
Assignee |
Filing Date |
Focus |
Status |
| US 9,761,976 |
"HSP90 inhibitors for cancer" |
Novartis |
August 2014 |
N-aryl and N-alkyl substituted HSP90 inhibitors |
Granted |
| US 9,724,300 |
"Combination therapies involving HSP90 inhibitors" |
AstraZeneca |
February 2015 |
Combining HSP90 inhibitors with chemotherapeutics |
Granted |
| WO 2018/203947 |
"Methods of treating cancer with HSP90 inhibitors" |
Genentech |
June 2018 |
Particular chemical scaffolds and combination treatments |
Published Patent Application |
Patent Filing Trends
- The earliest filings date back to the early 2010s, with a surge in filings around 2014–2018, reflecting substantial R&D investment.
- Major pharmaceutical companies such as Novartis, AstraZeneca, and Genentech have active patent portfolios.
- The focus has shifted from broad HSP90 inhibition compounds toward selective inhibitors with improved pharmacokinetics and safety profiles.
Patent Overlap and Freedom to Operate
- Numerous patents claim overlapping chemical scaffolds and therapeutic methods, indicating a dense landscape.
- The '165 patent's claims are specific to chemical structures not fully encompassed by broader patents, providing some freedom in that niche.
- However, infringement risks exist when implementing compounds with similar structural cores or use cases claimed in prior art.
Patentability and Innovation
The '165 patent's claims are supported by specific chemical disclosures that distinguish them from prior art, such as unique substitutions and treatment methods. The patent emphasizes:
- Structural novelty and non-obviousness based on chemical modifications.
- Specific dosing regimens and combinations that were not previously claimed or disclosed.
- Utility in treating multiple cancer types with particular combinations.
Market and R&D Implications
The patent supports a targeted approach for cancer therapy, especially for tumors resistant to conventional treatments. Its scope indicates potential to:
- Enable development of proprietary HSP90 inhibitors with optimized effects.
- Facilitate combination therapy patents.
- Secure market exclusivity in the niche of HSP90-based therapeutics.
Key Takeaways
- The '165 patent claims a specific class of chemical HSP90 inhibitors and methods of treatment involving their use.
- It fits within a competitive landscape with numerous patents on similar compounds but emphasizes structural innovations and treatment regimens.
- Its scope could be limited by prior patents, but the specific features outlined offer potential for licensing or further development.
- The patent’s focus on combination therapies and particular cancer types aligns with current trends in personalized medicine.
FAQs
1. Are the compounds claimed in Patent 10,576,165 structurally unique compared to prior art?
Yes. The patent discloses specific substitutions and stereochemical configurations that differentiate it from earlier HSP90 inhibitors.
2. Does the patent cover all types of cancer?
No. It specifically claims treatment of a range of tumors, including breast, lung, colon, and prostate, but does not broadly cover all cancers.
3. Can this patent be challenged on obviousness grounds?
Potentially. Given the extensive prior art on HSP90 inhibitors, claims may be challenged if prior art discloses similar structures or treatment methods.
4. How does this patent impact freedom to operate?
It restricts the development and commercialization of similar compounds with matching structural features during the patent term. A comprehensive landscape analysis is warranted.
5. What is the status of ongoing patent applications related to this patent?
No pending applications directly citing or building upon this patent are publicly available as of now. Continuous monitoring is recommended.
References
[1] US Patent 10,576,165.
[2] Patent landscapes and filings from the USPTO and WIPO patent databases.
[3] Industry reports on HSP90 inhibitors development.
